HYFT
ImmunoPrecise Antibodies Ltd.
NASDAQ: HYFT · HEALTHCARE · BIOTECHNOLOGY
$1.30
-4.41% today
Updated 2026-07-29
Market cap
$65.86M
P/E ratio
—
P/S ratio
2.35x
EPS (TTM)
$-0.10
Dividend yield
—
52W range
$1 – $3
Volume
0.4M
ImmunoPrecise Antibodies Ltd. (HYFT) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
-33.5%
Most recent quarter
EPS YoY growth
+87.0%
Most recent quarter
When is the next earnings report?
Reporting date
April 30, 2026
Consensus EPS estimate
$-0.05
Fiscal period ending
2026-04-30
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-4.1%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.1%
2025-12-15
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-12 | $-0.06 | -50.0% | $1.28 | $1.24 | -3.1% |
| 2025-12-15 | $-0.05 | -400.0% | $1.77 | $1.68 | -5.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-04-30 | $-0.05 | — | — | — | — |
| 2026-01-31 | $-0.04 | $-0.06 | -50.0% | $4.09M | -33.5% |
| 2025-10-31 | $-0.01 | $-0.05 | -400.0% | $4.12M | +53.9% |
| 2025-07-31 | $-0.04 | $-0.09 | -109.3% | $3.16M | +27.8% |
| 2025-04-30 | $-0.04 | $-0.04 | +0.0% | $6.98M | +8.1% |
| 2025-01-31 | $-0.06 | $-0.46 | -666.7% | $6.15M | -1.1% |
| 2024-10-31 | $-0.07 | $-0.06 | +14.3% | $2.68M | -56.4% |
| 2024-07-31 | — | $-0.11 | — | $2.47M | — |
| 2024-04-30 | $-0.08 | $-0.10 | -25.0% | $6.46M | — |
| 2024-01-31 | $-0.07 | $-0.08 | -14.3% | $6.22M | — |
| 2023-10-31 | $-0.10 | $-0.07 | +30.0% | $6.15M | — |
Frequently asked questions
When does ImmunoPrecise Antibodies Ltd. report next earnings?
ImmunoPrecise Antibodies Ltd. (HYFT) is scheduled to report earnings on April 30, 2026. The consensus EPS estimate is $-0.05.
Has ImmunoPrecise Antibodies Ltd. beaten earnings estimates?
ImmunoPrecise Antibodies Ltd. has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does HYFT stock react to earnings?
HYFT has moved an average of -4.1% the day after earnings over its last 2 reports, finishing higher after 0 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.
What is ImmunoPrecise Antibodies Ltd.'s revenue growth rate?
ImmunoPrecise Antibodies Ltd. reported year-over-year revenue growth of -33.5% in its most recent quarter, with EPS up +87.0%. EPS outpacing revenue is operating leverage at work, meaning profit is compounding faster than sales.